Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines

Robert J. Morgan, Ronald D. Alvarez, Deborah Kay Armstrong, Robert A. Burger, Mariana Castells, Lee May Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul SabbatiniJoseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, Mary A. Dwyer

Research output: Contribution to journalArticle

Abstract

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

Original languageEnglish (US)
Pages (from-to)1339-1349
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number11
StatePublished - Nov 1 2012

Fingerprint

Ovarian Neoplasms
Guidelines
Drug Hypersensitivity
Neoadjuvant Therapy
Disease Management
Combination Drug Therapy
Practice Guidelines
Routine Diagnostic Tests
Clinical Trials
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Castells, M., Chen, L. M., ... Dwyer, M. A. (2012). Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 10(11), 1339-1349.

Ovarian cancer, version 3.2012 : Featured updates to the NCCN guidelines. / Morgan, Robert J.; Alvarez, Ronald D.; Armstrong, Deborah Kay; Burger, Robert A.; Castells, Mariana; Chen, Lee May; Copeland, Larry; Crispens, Marta Ann; Gershenson, David; Gray, Heidi; Hakam, Ardeshir; Havrilesky, Laura J.; Johnston, Carolyn; Lele, Shashikant; Martin, Lainie; Matulonis, Ursula A.; O'Malley, David M.; Penson, Richard T.; Remmenga, Steven W.; Sabbatini, Paul; Santoso, Joseph T.; Schilder, Russell J.; Schink, Julian; Teng, Nelson; Werner, Theresa L.; Hughes, Miranda; Dwyer, Mary A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 10, No. 11, 01.11.2012, p. 1339-1349.

Research output: Contribution to journalArticle

Morgan, RJ, Alvarez, RD, Armstrong, DK, Burger, RA, Castells, M, Chen, LM, Copeland, L, Crispens, MA, Gershenson, D, Gray, H, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Remmenga, SW, Sabbatini, P, Santoso, JT, Schilder, RJ, Schink, J, Teng, N, Werner, TL, Hughes, M & Dwyer, MA 2012, 'Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 11, pp. 1339-1349.
Morgan, Robert J. ; Alvarez, Ronald D. ; Armstrong, Deborah Kay ; Burger, Robert A. ; Castells, Mariana ; Chen, Lee May ; Copeland, Larry ; Crispens, Marta Ann ; Gershenson, David ; Gray, Heidi ; Hakam, Ardeshir ; Havrilesky, Laura J. ; Johnston, Carolyn ; Lele, Shashikant ; Martin, Lainie ; Matulonis, Ursula A. ; O'Malley, David M. ; Penson, Richard T. ; Remmenga, Steven W. ; Sabbatini, Paul ; Santoso, Joseph T. ; Schilder, Russell J. ; Schink, Julian ; Teng, Nelson ; Werner, Theresa L. ; Hughes, Miranda ; Dwyer, Mary A. / Ovarian cancer, version 3.2012 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2012 ; Vol. 10, No. 11. pp. 1339-1349.
@article{1d68f391d8d14a13b1edf34ace982b68,
title = "Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See {"}Updates{"} in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.",
author = "Morgan, {Robert J.} and Alvarez, {Ronald D.} and Armstrong, {Deborah Kay} and Burger, {Robert A.} and Mariana Castells and Chen, {Lee May} and Larry Copeland and Crispens, {Marta Ann} and David Gershenson and Heidi Gray and Ardeshir Hakam and Havrilesky, {Laura J.} and Carolyn Johnston and Shashikant Lele and Lainie Martin and Matulonis, {Ursula A.} and O'Malley, {David M.} and Penson, {Richard T.} and Remmenga, {Steven W.} and Paul Sabbatini and Santoso, {Joseph T.} and Schilder, {Russell J.} and Julian Schink and Nelson Teng and Werner, {Theresa L.} and Miranda Hughes and Dwyer, {Mary A.}",
year = "2012",
month = "11",
day = "1",
language = "English (US)",
volume = "10",
pages = "1339--1349",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "11",

}

TY - JOUR

T1 - Ovarian cancer, version 3.2012

T2 - Featured updates to the NCCN guidelines

AU - Morgan, Robert J.

AU - Alvarez, Ronald D.

AU - Armstrong, Deborah Kay

AU - Burger, Robert A.

AU - Castells, Mariana

AU - Chen, Lee May

AU - Copeland, Larry

AU - Crispens, Marta Ann

AU - Gershenson, David

AU - Gray, Heidi

AU - Hakam, Ardeshir

AU - Havrilesky, Laura J.

AU - Johnston, Carolyn

AU - Lele, Shashikant

AU - Martin, Lainie

AU - Matulonis, Ursula A.

AU - O'Malley, David M.

AU - Penson, Richard T.

AU - Remmenga, Steven W.

AU - Sabbatini, Paul

AU - Santoso, Joseph T.

AU - Schilder, Russell J.

AU - Schink, Julian

AU - Teng, Nelson

AU - Werner, Theresa L.

AU - Hughes, Miranda

AU - Dwyer, Mary A.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

AB - These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

UR - http://www.scopus.com/inward/record.url?scp=84871415258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871415258&partnerID=8YFLogxK

M3 - Article

C2 - 23138163

AN - SCOPUS:84871415258

VL - 10

SP - 1339

EP - 1349

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 11

ER -